drugset
drugset / Trial / NCT03930602

Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165

NCT03930602 ↗

Phase 1 Completed 16 enrolled Bristol-Myers Squibb
Non-randomizedSequentialOpen-labelOther

Summary

To compare the pharmacokinetic characteristics of BMS-986165 after a single-dose administration alone vs. in combination with fluvoxamine (CYP1A2 inhibitor)

Timeline

Start
2019-05-01
Primary completion
2019-05-27
Completion
2019-05-27

Drugs

EvaluationDrugModalityDoseRoute
Subject CRAVACITINIB Small molecule — —
Subject Fluvoxamine Unknown — —

Indications

No indication recorded.